Among them, sodium-glucose cotransporter 2 (SGLT2) inhibitors provide effective treatment in all stages of T2DM regardless of blood glucose levels and benefit the cardiovascular system. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.